Skip to main content
QURE
NASDAQ Life Sciences

uniQure's Lead HD Program AMT-130 Faces FDA Setback, ALS Program Discontinued Amid Q1 Loss; Strong Cash Runway Maintained

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$20.89
Mkt Cap
$1.274B
52W Low
$8.73
52W High
$71.5
52W Position info
139% above low
Off High info
71% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

QURE has more than doubled off its 52-week low of $8.73.

Summary

uniQure reported an increased Q1 net loss and a significant FDA setback for its lead Huntington's disease candidate, AMT-130, requiring a new trial. The company also discontinued its AMT-162 ALS program but affirmed a strong cash runway into the second half of 2029.


Key Events · Product Development and Regulatory · QURE

  • FDA Setback for Lead Candidate AMT-130

    The FDA determined that Phase I/II data for AMT-130 in Huntington's disease is insufficient to support a marketing application, requiring a new clinical trial. A Type B meeting is scheduled for Q2 2026 to discuss new trial design.

  • Discontinuation of AMT-162 ALS Program

    Development of the AMT-162 program for SOD1 amyotrophic lateral sclerosis (ALS) has been discontinued following a dose-limiting toxicity observed in a patient during the Phase I/II EPISOD1 trial.

  • Strong Cash Runway Maintained

    uniQure reported $586.6 million in cash, cash equivalents, and current investment securities as of March 31, 2026, providing a cash runway into the second half of 2029.

  • Progress in UK Regulatory Path for AMT-130

    Following a successful pre-submission meeting with the UK MHRA, the company expects to submit a Marketing Authorization Application (MAA) for AMT-130 in the third quarter of 2026.


Analysis · QURE · Life Sciences

This filing reveals significant clinical setbacks for uniQure's pipeline, particularly for its lead Huntington's disease candidate, AMT-130, which the FDA has deemed insufficient for a marketing application based on current Phase I/II data, necessitating a new trial. The outright discontinuation of the AMT-162 ALS program due to safety concerns further compounds the negative clinical news. While the company reported an increased net loss for Q1 2026, the affirmation of a strong cash runway into the second half of 2029 is a critical mitigating factor, providing the financial stability needed to navigate these challenges and fund future trials. Investors should monitor the outcome of the upcoming FDA Type B meeting for AMT-130 and the progress of the UK regulatory path, as well as the upcoming AMT-260 data.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QURE was trading at $20.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QURE - Latest Insights

QURE
Nov 04, 2026, 7:28 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.60
Real-time Price: $24.80 info
Change: +$2.20 (+10%) info
Market Cap: $1.724B info
QURE
Nov 04, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.44
Real-time Price: $24.80 info
Change: +$2.36 (+11%) info
Market Cap: $1.724B info
QURE
Nov 02, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $27.66
Real-time Price: $24.80 info
Change: -$2.86 (-10%) info
Market Cap: $1.724B info
QURE
Sep 29, 2026, 9:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $22.00
Real-time Price: $24.80 info
Change: +$2.80 (+13%) info
Market Cap: $1.724B info
QURE
Sep 29, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.20
Real-time Price: $24.80 info
Change: +$2.60 (+12%) info
Market Cap: $1.724B info